JAG1 and cancer: The further characterization of these CARs revealed that engineered primary CAR-T cells expressing the J1.B5 Ab scFv in a third-generation design became activated only in the presence of JAG1-expressing cells and effectively and specifically killed JAG1-positive cancer cells.